Sanofi turns to G-BA for Jevtana benefits decision after vague IQWiG's assessment
This article was originally published in Scrip
Sanofi'sJevtana (cabazitaxel) could offer considerable additional benefit for castration-resistant prostate cancer patients aged 65 and over who are unable to continue with docetaxel (Sanofi's Taxotere), says IQWiG, the German HTA institute. Meanwhile, for patients under 65 there is just a "hint" of unquantifiable benefit. The assessment is vague and leaves too much scope for interpretation, says EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.